Tetraphase Presents Data Demonstrating Robust Activity and Dosing Flexibility of Intravenous and Oral Next-Generation Antibiotic Candidates Targeting Complicated, Multidrug-Resistant Pathogens

- Presentations at the 21st ECCMID Highlight Activity of TP-434 in Both I.V. and Oral Step-Down Therapies and Potency and Oral Activity of TP-2758 Against Multidrug-Resistant Gram-Negative Pathogens -

WATERTOWN, Mass.--(BUSINESS WIRE)--May 9, 2011 - Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on next-generation antibiotics, announced today that it is presenting new results of several studies designed to support the continued advancement of its lead antibiotic, TP-434, a potent new broad-spectrum intravenous (I.V.) antibiotic with oral stepdown potential effective against difficult-to-treat and multidrug-resistant pathogens. Tetraphase also is presenting results of pre-clinical evaluations of TP-2758, the company's second novel antibiotic, which is an oral agent for complicated urinary tract infections (cUTI). These data were described in an oral podium presentation and four poster presentations at the 21st European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in Milan, Italy.

"We continue to expand our data set, in both preclinical models and human studies, confirming the robust efficacy and dosing flexibility of our lead compounds – in oral and I.V. formulations – against multi-drug resistant bacterial pathogens," said Guy Macdonald, President and Chief Executive Officer. "In an effort to deliver solutions to the global health crisis caused by antibiotic resistance, we are applying these insights to the refinement of our mid- stage clinical program for TP-434 for complicated intra-abdominal infections and to the design of an efficient clinical pathway for TP-2758 as a treatment for cUTIs."

Data Summary:

(Full details on titles and times for Tetraphase abstracts can be found on the ECCMID Conference website at http://registration.akm.ch/einsicht.php.)

 

  • “Broad-spectrum fluorocycline TP-434 has oral bioavailability in humans.” A. Leighton, I. Zupanets, N. Bezugla, L. Plamondon, G. Macdonald, J. Sutcliffe – Presented as a poster (#1509) on Monday, May 9: In results from a double-blind, placebo-controlled, single-ascending dose study in healthy men and women, TP-434 showed promising oral bioavailability, reaching exposures predicted to be therapeutically efficacious without producing serious adverse events. This study confirmed the feasibility of development of an oral formulation of TP-434.
  • “The novel broad-spectrum fluorocycline TP-434 is active against MDR Gram-negative pathogens.” C. Fyfe, T. Grossman, W. O'Brien, C. Achorn, J. Sutcliffe – Presented as a poster (#1149) on Sunday, May 8: TP434 showed superior in vitro activity versus clinical comparators, including tigecyline, against important multi-drug resistant gram-negative pathogens such as Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBL+) and/or carbapenamases, MDR Acinetobacter baumannii, and anaerobic bacteria such as Bacteroides fragilis. These findings support the continued development of TP-434 in Phase II clinical trials for complicated intra-abdominal infections.
  • “The effects of varying susceptibility test parameters on TP-434 activity in vitro.” C. Pillar, D.H. Sahm, T. Grossman, J. Sutcliffe – Presented as a poster (#762) on Saturday, May 7: The in vitro antibacterial activity of TP-434 was shown to be largely unaffected by media age and media additives, unlike tigecycline, in an evaluation of the impact of variations in in vitro susceptibility test parameters.
  • “TP-2758 is a novel oral tetracycline targeting complicated urinary tract infections and pyelonephritis.” J. Sutcliffe, Y. Deng, M. Ronn, X. Xiao - Presented as an oral presentation (#96) on Saturday, May 7: TP-2758 showed promising oral bioavailability in two animal species (rat and monkey) and oral antimicrobial activity equivalent to I.V. meropenem in a mouse urinary tract infection (UTI)/kidney infection model.
  • In vitro activity of TP-2758 against panels of recent bacterial clinical isolates.” T. Grossman, W. O'Brien, C. Fyfe, C. Sun, W. Zhang, J. Sutcliffe – Presented as a poster (#1142) on Sunday, May 8: TP-2758 demonstrated two- to four-fold greater in vitro potency against important gram-negative pathogens, including Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBL+), than tigecycline. TP-2758 was two- to 32-fold less active against gram-positive pathogens than tigecycline.

About TP-434

TP-434, the lead product candidate in Tetraphase's clinical pipeline, is a potent new antibiotic effective against multidrug-resistant gram-negative pathogens. TP-434 is also effective against the broadest spectrum of other difficult-to-treat and multidrug-resistant pathogens, including multidrug-resistant gram-positive, anaerobic, and atypical species. TP-434's spectrum and pharmacokinetic properties are consistent with its use as a once-daily monotherapy. Preliminary Phase I data have shown that TP-434 also has the potential to be developed as an oral therapy. TP-434 I.V. is currently in Phase II clinical development.

About TP-2758

Novel antibiotic TP-2758 is in development as an I.V./oral compound specifically targeted as empiric monotherapy in complicated urinary tract infections (cUTIs). Tetraphase anticipates initiating Phase I trials with TP-2758 during the first half of 2011.

cUTI represents a category of bacterial infections with a high incidence of gram-negative pathogens. A rise in infections involving difficult-to-treat, resistant gram-negative pathogens has severely limited available treatment options, especially with an oral stepdown option.

About Tetraphase Pharmaceuticals, Inc.

Tetraphase Pharmaceuticals is a clinical-stage biopharmaceutical company utilizing its breakthrough synthetic chemistry technology platform to discover and develop next-generation tetracycline antibiotics that address unmet needs for serious infections such as drug resistance and Gram-negative infections. The company has developed an emerging pipeline of potent novel antibiotics that provide a portfolio of intravenous and oral drug candidates with the potential to treat a wide range of infections, including broad-spectrum and selective-spectrum infections. To learn more about Tetraphase, please visit www.tphase.com.

 

Contact: Tetraphase Pharmaceuticals, Inc.
Media Contact:
Sam Brown Inc.
Mike Beyer, 773-463-4211
beyer@sambrown.com

 

 

Posted: May 2011

View comments

Hide
(web2)